Health Care • Biotechnology: Pharmaceutical Preparations
$10.75 ▲ +0.11
(+1.03%)
MKT CAP: $1.96B • VOL: 1.75M
52W L $5 52W H $11
XERS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $291.8M | $203.1M | $163.9M |
| YoY Revenue Growth % | +43.7% | +23.9% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $24.9M | -$33.6M | -$44.0M |
| Operating Margin % | 8.5% | -16.6% | -26.8% |
| Net Income (GAAP) | $554.0K | -$54.8M | -$62.3M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $28.6M | -$37.0M | -$47.0M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $28.6M | -$37.0M | -$47.0M |
| FCF Margin % | 9.8% | -18.2% | -28.7% |
| Return on Invested Capital (ROIC %) | 16.0% | -23.0% | — |
| Cash & Short-Term Equivalents | $111.0M | $71.6M | — |
| Total Debt (Short + Long Term) | $220.3M | $217.0M | — |
| Total Stockholders' Equity | $13.7M | -$29.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR XERS.